Zenrelia 4.8 mg Pet Meds Tablets | sku-14769368899

Zenrelia 4.8 mg tablets (4.8mg), sku-14769368899, are Pet Meds for dogs; UPC 466140323919. The active ingredient, ilunocitinib, reduces the itch and inflammatory response in skin affected by allergies. Zenrelia relieves itching due to allergic dermatitis and controls atopic dermatitis. A cited study reports visible improvement in itch: Forster S, Boegel A, Despa S, et al., Veterinary Dermatology, 2025; 1 to 10. The tablet is given once daily, with or without food. The most common reported side effects are vomiting, diarrhea and tiredness; see the package insert, including its Boxed Warning. SAFETY WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. A vaccine response study found that dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and an inadequate immune response to any vaccine. Discontinue Zenrelia at least 28 days to 3 months before vaccination and withhold it for at least 28 days afterward. Dogs should be up to date on vaccinations before starting treatment. Do not use it in dogs less than 12 months old or in dogs with a serious infection. Monitor dogs for infections, as Zenrelia may increase the chance of infection. Benign and malignant neoplastic conditions were observed in clinical studies. Zenrelia has not been tested in breeding, pregnant or lactating dogs, or evaluated in combination with glucocorticoids, cyclosporine or other immunosuppressive drugs.